Empery Asset Management LP Acquires Shares of 2,674,950 Immuneering Corporation $IMRX

Empery Asset Management LP acquired a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) in the fourth quarter, Holdings Channel.com reports. The firm acquired 2,674,950 shares of the company’s stock, valued at approximately $17,601,000. Immuneering makes up about 15.6% of Empery Asset Management LP’s portfolio, making the stock its 2nd largest position.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after buying an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Immuneering during the 3rd quarter valued at about $6,602,000. Blue Owl Capital Holdings LP grew its position in shares of Immuneering by 20.9% during the 4th quarter. Blue Owl Capital Holdings LP now owns 665,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 115,000 shares during the period. Geode Capital Management LLC grew its position in shares of Immuneering by 20.3% during the 4th quarter. Geode Capital Management LLC now owns 618,074 shares of the company’s stock valued at $4,068,000 after acquiring an additional 104,409 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Immuneering during the 4th quarter valued at about $2,098,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Wall Street Analysts Forecast Growth

IMRX has been the topic of a number of analyst reports. Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Immuneering in a research report on Monday, March 9th. Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. Finally, Oppenheimer restated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Trading Down 2.7%

IMRX stock opened at $3.92 on Thursday. Immuneering Corporation has a 12-month low of $1.66 and a 12-month high of $10.08. The stock has a market cap of $253.62 million, a price-to-earnings ratio of -3.35 and a beta of 0.38. The business’s 50-day moving average is $5.21 and its 200 day moving average is $5.46.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.09. As a group, equities analysts forecast that Immuneering Corporation will post -1.12 EPS for the current fiscal year.

Immuneering Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.